NCT06404918

Brief Summary

Modified radical mastectomy (MRM) is one of the most performed surgeries for breast cancer. MRM is associated with significant pain during the immediate postoperative period.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 22, 2023

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 22, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 3, 2024

Completed
28 days until next milestone

First Submitted

Initial submission to the registry

May 1, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 8, 2024

Completed
Last Updated

May 8, 2024

Status Verified

April 1, 2024

Enrollment Period

1.1 years

First QC Date

May 1, 2024

Last Update Submit

May 4, 2024

Conditions

Keywords

Erector Spinae Plane BlockSerratus Anterior Plane Block

Outcome Measures

Primary Outcomes (1)

  • time of the first rescue analgesic dose

    The time when the first dose of rescue analgesia was administered at the recovery room,

    24 hours postoperatively

Secondary Outcomes (2)

  • Heart rate changes

    15 minutes after performing the block, and then every 30 minutes intraoperatively till the end of surgery, then postoperatively at 1hour and 2 hours, 4hours, 8hours, 12hours, 18hours, 24hours postoperatively.

  • Mean arterial pressure changes

    15 minutes after performing the block, and then every 30 minutes intraoperatively till the end of surgery, then postoperatively at 1hour and 2 hours, 4hours, 8hours, 12hours, 18hours, 24hours postoperatively.

Study Arms (2)

Erector spinae plane group

EXPERIMENTAL

The patients were placed in lateral decubitus position with the operation site up. The probe was placed vertically 3 cm lateral to the T5 spinous process, and the transverse process was identified as an oval hyperechoic sonographic structure. The needle was introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. 0.5 mL of normal saline was injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. A total of 0.4 mL kg-1 of 0.25% bupivacaine was injected. between the erector spinae muscle and transverse process.

Procedure: Erector spinae plane group

Serratus anterior plane group

EXPERIMENTAL

Serratus anterior plane block was administered to patient in the supine position with ipsilateral arm abducted to 90°. Under aseptic precautions, linear probe was placed over the midclavicular region in the sagittal plane. Ribs were counted inferiorly and laterally until the fifth rib was identified in midaxillary line. Latissimus dorsi, teres major, and serratus anterior muscles were identified overlying the fifth rib. The intended puncture site was infiltrated with 2 mL of 2% lignocaine, and using ultrasound-guided in-plane approach, the needle was introduced in caudal to cranial direction until the tip was placed between the serratus anterior muscle and external intercostal muscle.

Procedure: Serratus anterior plane group

Interventions

The patients were placed in lateral decubitus position with the operation site up. The probe was placed vertically 3 cm lateral to the T5 spinous process, and the transverse process was identified as an oval hyperechoic sonographic structure. The needle was introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. 0.5 mL of normal saline was injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. A total of 0.4 mL kg-1 of 0.25% bupivacaine was injected. between the erector spinae muscle and transverse process.

Also known as: US ESPB group
Erector spinae plane group

Serratus anterior plane block was administered to patient in the supine position with ipsilateral arm abducted to 90°. Under aseptic precautions, linear probe was placed over the midclavicular region in the sagittal plane. Ribs were counted inferiorly and laterally until the fifth rib was identified in midaxillary line. Latissimus dorsi, teres major, and serratus anterior muscles were identified overlying the fifth rib. The intended puncture site was infiltrated with 2 mL of 2% lignocaine, and using ultrasound-guided in-plane approach, the needle was introduced in caudal to cranial direction until the tip was placed between the serratus anterior muscle and external intercostal muscle.

Also known as: USAPB group
Serratus anterior plane group

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • female patients
  • aged from 18 to 70 years
  • with a body mass index ≤ 30 kg/ m2
  • American Society of Anesthesiologists (ASA) physical status I-II,
  • who were scheduled for MRM for breast cancer

You may not qualify if:

  • history of drug allergy,
  • psychiatric illness, substance abuse,
  • severe cardiovascular or respiratory disease,
  • any pre-existing liver disease, metabolic or neurological syndrome, c

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Benha University

Banhā, 13511, Egypt

Location

Study Officials

  • Ramy Saleh, MD

    Anesthesia and surgical ICU department, Faculty of Medicine, Benha University, Egypt

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Masking Details
The patients and Care Provider in this trial were blinded
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Group I (35 patients): patients received US ESPB and group II (35 patients): patients received USAPB.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

May 1, 2024

First Posted

May 8, 2024

Study Start

January 22, 2023

Primary Completion

February 22, 2024

Study Completion

April 3, 2024

Last Updated

May 8, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Locations